biostudies-literaturePinato DJCancer Research UKInstituto de Salud Carlos IIIImperial Experimental Cancer Medicine Centre, Cancer Research UKWellcome TrustImperial College Healthcare NHS Truste003311https://www.ebi.ac.uk/biostudies/studies/S-EPMC8487214biostudies-literatureUnknown9(9)<h4>Background</h4>Modulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by phenotypic lymphocyte characterization in samples of patients undergoing surgery with (T+) or without (T-) prior-TACE treatment.<h4>Methods</h4>We profiled intratumoral (IT), peritumoral (PT) and non-tumoral (NT) background tissue to evaluate regulatory CD4+/FOXP3+ (T-reg) and immune-exhausted CD8+/PD-1+ T-cells across T+ (n=58) and T- (n=61). We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples (n=24) evaluated in relationship with the expression of actionable drivers of anti-cancer immunity including PD-L1, indoleamine 2,3 dehydrogenase (IDO-1), cytotoxic T-lympJournal for immunotherapy of cancerTrans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.PMC8487214PS3416PI18/0054226137C57701/A26137Diaz ABhoori SMurray SMFessas PBoyton RJKaneko TMazzaferro VGoldin RDMarafioti TToniutto PGiannini EMinguez BAltmann DMMauri FAPinato DJAvellini CCacciato VAkarca AUGrillo FCasagrande EForner AfalseTrans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.<h4>Background</h4>Modulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by phenotypic lymphocyte characterization in samples of patients undergoing surgery with (T+) or without (T-) prior-TACE treatment.<h4>Methods</h4>We profiled intratumoral (IT), peritumoral (PT) and non-tumoral (NT) background tissue to evaluate regulatory CD4+/FOXP3+ (T-reg) and immune-exhausted CD8+/PD-1+ T-cells across T+ (n=58) and T- (n=61). We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples (n=24) evaluated in relationship with the expression of actionable drivers of anti-cancer immunity including PD-L1, indoleamine 2,3 dehydrogenase (IDO-1), cytotoxic T-lymp2021-01-01T00:00:00Z2021 Sep2026-06-13T06:29:11.775Z2026-06-13T03:12:15.078ZS-EPMC84872143459362110.1136/jitc-2021-003311